Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

304

Enrollment

INDUSTRY

Sponsor class

Conditions

Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Interventions

DRUG: Blinatumomab
DRUG: Low-intensity chemotherapy regimen
DRUG: SOC chemotherapy regimen

Sponsor

Amgen